Skip to main content
. 2017 Jan 17;2017(1):CD004143. doi: 10.1002/14651858.CD004143.pub5

Comparison 6. All women (selected outcomes: cancer, cholecystic disease, fractures).

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
1 Breast cancer: oestrogen‐only HT 7   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
1.1 Oestrogen only HRT patch 0.025 (low dose) mg daily for 2 years 1 176 Risk Ratio (M‐H, Fixed, 95% CI) 2.93 [0.12, 71.04]
1.2 Oestradiol 1 mg (low dose) for 2 years 1 222 Risk Ratio (M‐H, Fixed, 95% CI) 0.33 [0.01, 8.10]
1.3 Oestradiol valerate 2 mg (mod dose) for 2 years 1 1017 Risk Ratio (M‐H, Fixed, 95% CI) 0.98 [0.25, 3.91]
1.4 Oestradiol patch 0.075 mg (high dose) for 2 years 1 176 Risk Ratio (M‐H, Fixed, 95% CI) 2.93 [0.12, 71.04]
1.5 CEE 0.625 mg (mod dose) for 2.8‐3.2 years 3 676 Risk Ratio (M‐H, Fixed, 95% CI) 2.05 [0.38, 11.04]
1.6 CEE 0.625 mg (mod dose) for 7.1 years 1 10739 Risk Ratio (M‐H, Fixed, 95% CI) 0.79 [0.61, 1.01]
1.7 CEE 0.625 mg (mod dose) after 10.7 years (includes extra follow‐up) 1 10739 Risk Ratio (M‐H, Fixed, 95% CI) 0.78 [0.63, 0.96]
1.8 CEE 0.625 mg (mod dose) after 13 years (includes extra follow‐up) 1 10739 Risk Ratio (M‐H, Fixed, 95% CI) 0.80 [0.65, 0.97]
2 Breast cancer: oestrogen‐only or combined HT 1   Odds Ratio (M‐H, Fixed, 95% CI) Totals not selected
2.1 CEE 0.625 mg (mod dose) with or without 2.5 mg MPA for 3 years 1   Odds Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Breast cancer: combined continuous HT 5   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
3.1 CEE 0.625 mg (mod dose) + MPA 2.5 mg for mean/median 1 year 2 23182 Risk Ratio (M‐H, Fixed, 95% CI) 0.52 [0.28, 0.96]
3.2 CEE 0.625 mg (mod dose) + MPA 2.5 mg for 2 years 1 16608 Risk Ratio (M‐H, Fixed, 95% CI) 0.71 [0.47, 1.08]
3.3 CEE 0.625 mg (mod dose) + MPA 2.5 mg for 2.8‐3.4 years 3 17733 Risk Ratio (M‐H, Fixed, 95% CI) 0.85 [0.62, 1.18]
3.4 CEE 0.625 mg (mod dose) + MPA 2.5 mg for 4 years 1 2763 Risk Ratio (M‐H, Fixed, 95% CI) 1.36 [0.82, 2.27]
3.5 CEE 0.625 mg (mod dose) + MPA 2.5 mg for 5.6 years 1 16608 Risk Ratio (M‐H, Fixed, 95% CI) 1.27 [1.03, 1.56]
3.6 CEE 0.625 mg (mod dose) + MPA 2.5 mg for 4‐7 years unblinded 1 2321 Risk Ratio (M‐H, Fixed, 95% CI) 1.08 [0.52, 2.23]
3.7 CEE 0.625 mg (mod dose) + MPA 2.5 mg for 7.9 years 1 16607 Risk Ratio (M‐H, Fixed, 95% CI) 1.27 [1.07, 1.52]
3.8 CEE 0.625 mg (mod dose) + MPA 2.5 mg after 11 years (includes extra follow‐up) 1 16608 Risk Ratio (M‐H, Fixed, 95% CI) 1.25 [1.08, 1.45]
3.9 CEE 0.625 mg (mod dose) + MPA 2.5 mg after 13.2 years (includes extended follow up) 1 16608 Risk Ratio (M‐H, Fixed, 95% CI) 1.28 [1.11, 1.47]
4 Breast cancer: combined sequential HT 3   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
4.1 CEE 0.625 mg (mod dose) daily + MPA 10 mg days 1‐12 for 3 years 1 348 Risk Ratio (M‐H, Fixed, 95% CI) 2.0 [0.18, 21.85]
4.2 CEE 0.625 mg (mod dose) daily + micronised progesterone 200 mg days 1‐12 for 3 years 1 352 Risk Ratio (M‐H, Fixed, 95% CI) 3.91 [0.44, 34.64]
4.3 CEE 0.045 mg (lowish dose) + 200 mg sequential progesterone for 4 years 1 505 Risk Ratio (M‐H, Fixed, 95% CI) 1.79 [0.30, 10.64]
4.4 Oestradiol patch 0.05 mg (mod dose) + 200 mg sequential progesterone for 4 years 1 497 Risk Ratio (M‐H, Fixed, 95% CI) 1.86 [0.31, 11.02]
4.5 CEE 2.5 mg daily (high dose) + MPA 10 mg for 7 days each cycle for 10 years 1 168 Risk Ratio (M‐H, Fixed, 95% CI) 0.11 [0.01, 2.03]
5 Breast cancer: oestrogen with or without sequential progesterone vaginal gel 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
5.1 Oestradiol 1 mg daily, with or without cyclic 4% vaginal progesterone gel 1 643 Risk Ratio (M‐H, Fixed, 95% CI) 1.24 [0.50, 3.10]
6 Colorectal cancer: oestrogen‐only HT 2   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
6.1 CEE 0.625 mg (mod dose) for 3 years 1 349 Risk Ratio (M‐H, Fixed, 95% CI) 0.33 [0.01, 8.08]
6.2 CEE 0.625 (mod dose) for 7.1 years 1 10739 Risk Ratio (M‐H, Fixed, 95% CI) 1.15 [0.81, 1.63]
6.3 CEE 0.625 mg (mod dose) for 10.7 years (includes extra follow‐up) 1 10739 Risk Ratio (M‐H, Fixed, 95% CI) 1.11 [0.82, 1.49]
7 Colorectal cancer: oestrogen‐only or combined HT 1   Odds Ratio (M‐H, Fixed, 95% CI) Totals not selected
7.1 CEE 0.625 mg (mod dose) with or without 2.5 mg MPA for 3 years 1   Odds Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Colorectal cancer: combined continuous HT 4   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
8.1 CEE 0.625 mg (mod dose) + MPA 2.5 mg for mean/median 1 year 2 20993 Risk Ratio (M‐H, Fixed, 95% CI) 0.68 [0.32, 1.42]
8.2 CEE 0.625 mg (mod dose) + MPA 2.5 mg for 2 years 1 16608 Risk Ratio (M‐H, Fixed, 95% CI) 0.83 [0.46, 1.50]
8.3 CEE 0.625 mg (mod dose) + MPA 2.5 mg for 3 years 2 16956 Risk Ratio (M‐H, Fixed, 95% CI) 0.81 [0.49, 1.34]
8.4 CEE 0.625 mg (mod dose) + 2.5 mg MPA for 4 years 1 2763 Risk Ratio (M‐H, Fixed, 95% CI) 0.69 [0.32, 1.48]
8.5 CEE 0.625 mg (mod dose) + MPA 2.5 mg for mean 5.6 years 1 16608 Risk Ratio (M‐H, Fixed, 95% CI) 0.64 [0.44, 0.91]
8.6 CEE 0.625 mg (mod dose) + 2.5 mg MPA for 4‐6.8 years UNBLINDED 1 2321 Risk Ratio (M‐H, Fixed, 95% CI) 0.81 [0.46, 1.44]
8.7 CEE 0.625 mg (mod dose) + MPA 2.5 mg after 7.9 years (includes extended follow‐up) 1 16608 Risk Ratio (M‐H, Fixed, 95% CI) 0.76 [0.57, 1.01]
8.8 CEE 0.0625 mg (mod dose) + MPA 2.5 mg after 11.6 years (includes extended follow‐up) 1 16608 Risk Ratio (M‐H, Fixed, 95% CI) 0.78 [0.61, 0.99]
8.9 CEE 0.0625 mg (mod dose) + MPA 2.5 mg after 13.2 years (includes extended follow‐up) 1 16608 Risk Ratio (M‐H, Fixed, 95% CI) 0.80 [0.63, 1.01]
9 Colorectal cancer: combined sequential HT 2   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
9.1 CEE 0.625 mg (mod dose) daily + MPA 10 mg days 1‐12 for 3 years 1 348 Risk Ratio (M‐H, Fixed, 95% CI) 0.33 [0.01, 8.13]
9.2 CEE 0.625 mg (mod dose) daily + micronised progesterone 200 mg days 1‐12 for 3 years 1 352 Risk Ratio (M‐H, Fixed, 95% CI) 0.33 [0.01, 7.95]
9.3 CEE 2.5 mg (high dose) daily + MPA 10 mg for 7 days each cycle for 10 years 1 168 Risk Ratio (M‐H, Fixed, 95% CI) 1.0 [0.06, 15.73]
10 Colorectal cancer: oestrogen with or without sequential progesterone vaginal gel 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
10.1 Oestradiol 1 mg daily, with or without cyclic 4% vaginal progesterone gel 1 643 Risk Ratio (M‐H, Fixed, 95% CI) 1.49 [0.25, 8.83]
11 Lung cancer: oestrogen‐only HT (moderate dose) 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
11.1 Any lung cancer (non‐small cell or small cell) at 7.1 years 1 10739 Risk Ratio (M‐H, Fixed, 95% CI) 1.04 [0.73, 1.48]
12 Lung cancer: combined continuous HT (mod dose oestrogen) 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
12.1 Any lung cancer at 5.6 years (non‐small cell or small cell) 1 16608 Risk Ratio (M‐H, Fixed, 95% CI) 1.06 [0.77, 1.46]
12.2 Any lung cancer at 7.9 years 1 16608 Risk Ratio (M‐H, Fixed, 95% CI) 1.22 [0.92, 1.62]
12.3 Any lung cancer after median 14 years (includes extended follow‐up) 1 16608 Risk Ratio (M‐H, Fixed, 95% CI) 1.13 [0.93, 1.38]
13 Lung cancer: combined sequential HT 1   Odds Ratio (M‐H, Fixed, 95% CI) Subtotals only
13.1 17‐B‐oestradiol 1 mg (low dose) daily plus (3 days weekly) 0.35 mg norethindrone for 2 years 1 142 Odds Ratio (M‐H, Fixed, 95% CI) 3.13 [0.13, 78.13]
14 Endometrial cancer: oestrogen‐only HT 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
14.1 CEE 0.625 mg (mod dose) for 3‐3.2 years 1 238 Risk Ratio (M‐H, Fixed, 95% CI) 0.33 [0.01, 8.10]
15 Endometrial cancer: combined continuous HT (mode dose oestrogen) 3   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
15.1 CEE 0.625 mg + MPA 2.5 mg for 1 year 1 16608 Risk Ratio (M‐H, Fixed, 95% CI) 0.95 [0.13, 6.76]
15.2 CEE 0.625 mg + MPA 2.5 mg for 2 years 1 16608 Risk Ratio (M‐H, Fixed, 95% CI) 0.95 [0.31, 2.95]
15.3 CEE 0.625 mg + MPA 2.5 mg for 3‐3.2 years 2 16847 Risk Ratio (M‐H, Fixed, 95% CI) 0.80 [0.35, 1.82]
15.4 CEE 0.625 mg + MPA 2.5 mg for 4 years 1 2763 Risk Ratio (M‐H, Fixed, 95% CI) 0.40 [0.08, 2.06]
15.5 CEE 0.625 mg + MPA 2.5 mg for 5.6 years 1 16608 Risk Ratio (M‐H, Fixed, 95% CI) 0.86 [0.51, 1.44]
15.6 CEE 0.625 mg + MPA 2.5 mg for 4‐6.8 years UNBLINDED 1 2321 Risk Ratio (M‐H, Fixed, 95% CI) 0.14 [0.01, 2.78]
15.7 CEE 0.625 + MPS 2.5 mg for 7.9 years 1 16608 Risk Ratio (M‐H, Fixed, 95% CI) 0.81 [0.54, 1.20]
15.8 CEE 0.625 mg + MPA 2.5 mg after median 13 years (includes extended follow‐up) 1 16608 Risk Ratio (M‐H, Fixed, 95% CI) 0.66 [0.48, 0.90]
16 Endometrial cancer: combined sequential HT 4   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
16.1 17‐B‐oestradiol 1 mg (low dose) + dydrogesterone 5 mg days 14‐28 for 2 years 1 163 Risk Ratio (M‐H, Fixed, 95% CI) 1.90 [0.08, 45.95]
16.2 CEE 0.625 mg (mod dose) daily + micronised progesterone 200 mg days 1‐12 for 3 years 1 239 Risk Ratio (M‐H, Fixed, 95% CI) 0.33 [0.01, 8.03]
16.3 Oestradiol 2 mg (mod dose) + dihydrogesterone 20 mg for 2 years 1 159 Risk Ratio (M‐H, Fixed, 95% CI) 3.30 [0.16, 67.59]
16.4 CEE 0.045 mg (lowish dose) + 200 mg sequential progesterone for 4 years 1 505 Risk Ratio (M‐H, Fixed, 95% CI) 5.97 [0.29, 123.81]
16.5 Oestradiol patch 0.05 mg (mod dose) + 200 mg sequential progesterone for 4 years 1 497 Risk Ratio (M‐H, Fixed, 95% CI) 3.71 [0.15, 90.70]
16.6 CEE 2.5 mg (high dose) daily + MPA 10 mg for 7 days each cycle for 10 years 1 168 Risk Ratio (M‐H, Fixed, 95% CI) 0.33 [0.01, 8.07]
17 Recurrent endometrial cancer: oestrogen‐only HT 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
17.1 Oestrogen (type and dose not stated) for median 3 years 1 1236 Risk Ratio (M‐H, Fixed, 95% CI) 1.17 [0.54, 2.50]
18 Ovarian cancer: combined continuous HT 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
18.1 CEE 0.625 mg (mod dose) + MPA 2.5 mg for 5.6 years 1 16608 Risk Ratio (M‐H, Fixed, 95% CI) 1.43 [0.76, 2.69]
18.2 CEE 0.625 mg (mod dose) + MPA 2.5 mg after 13.2 years (includes extended follow‐up) 1 16608 Risk Ratio (M‐H, Fixed, 95% CI) 1.23 [0.82, 1.85]
19 Ovarian cancer: oestrogen with or without sequential progesterone vaginal gel 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
19.1 Oestradiol 1 mg daily, with or without cyclic 4% vaginal progesterone gel 1 643 Risk Ratio (M‐H, Fixed, 95% CI) 0.33 [0.01, 8.08]
20 Gallbladder disease requiring surgery: oestrogen‐only HT 3 8930 Risk Ratio (M‐H, Fixed, 95% CI) 1.75 [1.40, 2.19]
20.1 CEE 0.625 mg (mod dose) for 3‐3.2 years 2 554 Risk Ratio (M‐H, Fixed, 95% CI) 0.77 [0.17, 3.39]
20.2 CEE O.625 mg (mod dose) for 7.1 years 1 8376 Risk Ratio (M‐H, Fixed, 95% CI) 1.78 [1.42, 2.24]
21 Gallbladder disease requiring surgery: combined continuous HT 4   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
21.1 CEE 0.625 mg (mod dose) + 2.5 mg MPA for 3 years 2 557 Risk Ratio (M‐H, Fixed, 95% CI) 2.01 [0.61, 6.59]
21.2 CEE 0.625 mg (mod dose) + 2.5 mg MPA for 4 years 1 2253 Risk Ratio (M‐H, Fixed, 95% CI) 1.35 [0.98, 1.85]
21.3 CEE 0.625 mg (mod dose) + 2.5 mg MPA for mean 5.6 years 1 14203 Risk Ratio (M‐H, Fixed, 95% CI) 1.64 [1.30, 2.06]
22 Gallbladder disease requiring surgery: combined sequential HT 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
22.1 CEE 0.625 mg (mod dose) daily + MPA 10 mg days 1‐12 for 3 years 1 348 Risk Ratio (M‐H, Fixed, 95% CI) 2.0 [0.37, 10.78]
22.2 CEE 0.625 mg (mod dose) daily + micronised progesterone 200 mg days 1‐12 for 3 years 1 352 Risk Ratio (M‐H, Fixed, 95% CI) 1.47 [0.25, 8.67]
23 Hip fractures: oestrogen‐only HT 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
23.1 CEE 0.625 mg (mod dose) for 7.1 years 1 10739 Risk Ratio (M‐H, Fixed, 95% CI) 0.66 [0.46, 0.95]
23.2 CEE 0.625 mg (mod dose) for 10.7 years (includes extra follow‐up) 1 10739 Risk Ratio (M‐H, Fixed, 95% CI) 0.92 [0.71, 1.18]
23.3 CEE 0.625 mg (mod dose) after 13.2 years (includes extended follow‐up) 1 10739 Risk Ratio (M‐H, Fixed, 95% CI) 0.93 [0.74, 1.17]
24 Hip fractures: oestrogen‐only or combined sequential HT 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
24.1 Oestradiol 1 mg (low dose) daily (if no uterus) plus MPA 5 mg for 12 days a year (if uterus intact) for 2.8 years 1 664 Risk Ratio (M‐H, Fixed, 95% CI) 0.62 [0.27, 1.42]
25 Hip fractures: combined continuous HT 3   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
25.1 CEE 0.625 mg (mod dose) + MPA 2.5 mg for mean/median 1 year 2 20993 Risk Ratio (M‐H, Fixed, 95% CI) 0.64 [0.26, 1.57]
25.2 CEE 0.625 mg (mod dose) + MPA 2.5 mg for 2 years 1 16608 Risk Ratio (M‐H, Fixed, 95% CI) 0.61 [0.31, 1.18]
25.3 CEE 0.625 mg (mod dose) + MPA 2.5 mg for 3 years 1 16608 Risk Ratio (M‐H, Fixed, 95% CI) 0.70 [0.42, 1.17]
25.4 CEE 0.625 mg (mod dose) + MPA 2.5 mg for 4 years 1 2763 Risk Ratio (M‐H, Fixed, 95% CI) 1.16 [0.55, 2.42]
25.5 CEE 0.625 mg (mod dose) + MPA 2.5 mg for 5.6 years 1 16608 Risk Ratio (M‐H, Fixed, 95% CI) 0.67 [0.47, 0.96]
25.6 CEE 0.625 mg (mod dose) + MPA 2.5 mg for 4‐6.8 years UNBLINDED 1 2321 Risk Ratio (M‐H, Fixed, 95% CI) 2.10 [1.06, 4.16]
25.7 CEE 0.625 mg (mod dose) + 2.5 mg MPA for 7.9 years 1 16608 Risk Ratio (M‐H, Fixed, 95% CI) 0.77 [0.60, 0.99]
25.8 CEE 0.625 mg (mod dose) + 2.5 mg MPA after 13.2 years (includes extended follow‐up) 1 16608 Risk Ratio (M‐H, Fixed, 95% CI) 0.82 [0.69, 0.97]
26 Hip fractures: combined sequential HT 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
26.1 17‐B‐oestradiol 1 mg (low dose) daily plus (3 days weekly) 0.35 mg norethindrone for 2 years 1 142 Risk Ratio (M‐H, Fixed, 95% CI) 0.34 [0.01, 8.27]
27 Vertebral fractures: oestrogen‐only HT 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
27.1 CEE 0.625 mg (mod dose) for 7.1 years 1 10739 Risk Ratio (M‐H, Fixed, 95% CI) 0.64 [0.44, 0.94]
28 Vertebral fractures: combined continuous HT 2   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
28.1 CEE 0.625 mg (mod dose) + MPA 2.5 mg for 4 years 1 2763 Risk Ratio (M‐H, Fixed, 95% CI) 0.74 [0.37, 1.47]
28.2 CEE 0.625 mg (mod dose) + MPA 2.5 mg for mean 5.6 years 1 16608 Risk Ratio (M‐H, Fixed, 95% CI) 0.68 [0.49, 0.96]
28.3 CEE 0.625 mg (mod dose) + MPA 2.5 mg for 4‐6.8 years UNBLINDED 1 2321 Risk Ratio (M‐H, Fixed, 95% CI) 1.10 [0.49, 2.48]
28.4 CEE 0.625 mg (mod dose) + MPA 2.5 mg for mean 7.9 years 1 16608 Risk Ratio (M‐H, Fixed, 95% CI) 0.78 [0.60, 1.01]
29 All clinical fractures: oestrogen‐only or combined sequential HT 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
29.1 Oestradiol 1 mg (low dose) daily (if no uterus) plus MPA 5 mg for 12 days a year (if uterus intact) for 2.8 years 1 664 Risk Ratio (M‐H, Fixed, 95% CI) 1.23 [0.68, 2.19]
30 All clinical fractures: oestrogen‐only HT (moderate dose) 3   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
30.1 Oestradiol valerate 2 mg (mod dose) for 2 years 1 1017 Risk Ratio (M‐H, Fixed, 95% CI) 0.60 [0.29, 1.26]
30.2 CEE 0.625 mg (mod dose) daily for 3.2 years 1 205 Risk Ratio (M‐H, Fixed, 95% CI) 0.42 [0.17, 1.04]
30.3 CEE 0.625 mg (mod dose) for 7.1 years 1 10739 Risk Ratio (M‐H, Fixed, 95% CI) 0.73 [0.65, 0.80]
31 All clinical fractures: oestrogen‐only or combined HT 1   Risk Ratio (M‐H, Fixed, 95% CI) Totals not selected
31.1 CEE 0.625 mg (mod dose) with or without 2.5 mg MPA for 3 years 1   Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
32 All clinical fractures: combined continuous HT 5   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
32.1 CEE 0.625 mg (mod dose) + MPA 2.5 mg for median 1 year 1 4385 Risk Ratio (M‐H, Fixed, 95% CI) 0.69 [0.46, 1.02]
32.2 CEE 0.625 mg (mod dose) + MPA 2.5 mg for 3.2‐3.4 years 2 986 Risk Ratio (M‐H, Fixed, 95% CI) 0.52 [0.32, 0.87]
32.3 CEE 0.625 mg (mod dose) + MPA 2.5 mg for mean 5.6 years 1 16608 Risk Ratio (M‐H, Fixed, 95% CI) 0.78 [0.71, 0.86]
32.4 CEE 0.625 mg (mod dose) + MPA 2.5 mg for 4 years 1 2763 Risk Ratio (M‐H, Fixed, 95% CI) 0.95 [0.76, 1.18]
32.5 CEE 0.625 mg (mod dose) + MPA 2.5 mg for 4‐6.8 years UNBLINDED 1 2321 Risk Ratio (M‐H, Fixed, 95% CI) 1.23 [0.91, 1.65]
32.6 CEE 0.0625 mg (mod dose) + MPA 2.5 mg for mean 7.9 years 1 16608 Risk Ratio (M‐H, Fixed, 95% CI) 0.82 [0.76, 0.89]
33 All clinical fractures: combined sequential HT 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
33.1 17‐B‐oestradiol 1 mg (low dose) daily plus (3 days weekly) 0.35 mg norethindrone for 2 years 1 142 Risk Ratio (M‐H, Fixed, 95% CI) 0.44 [0.12, 1.64]